Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil

BMJ Open

Volumn 4, Issue 3, 2014, Pages

  Silveira, Miriam Sanches Do Nascimento ^a   De Camargo, Iara Alves ^a   Osorio de Castro, Claudia Garcia Serpa ^b   Barberato Filho, Silvio ^a   Del Fiol, Fernando De Sá ^a   Guyatt, Gordon ^c   De Camargo, Mayara Costa ^a   Lopes, Luciane Cruz ^a  

^a UNIVERSITY OF SOROCABA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CYCLOSPORIN A; ETRETIN; METHOTREXATE; ANTIINFLAMMATORY AGENT; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD CELL COUNT; BRAZIL; CLINICAL PRACTICE; COURT; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; GOVERNMENT; HEALTH CARE MANAGEMENT; HUMAN; INTERVIEW; LABORATORY TEST; LAW SUIT; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT MONITORING; PHARMACY; PHOTOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PSORIASIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG LEGISLATION; LEGISLATION AND JURISPRUDENCE; LIVER FUNCTION TEST; MIDDLE AGED; STANDARDS; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; BLOOD CELL COUNT; BRAZIL; FEMALE; GUIDELINE ADHERENCE; HUMANS; LEGISLATION, DRUG; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PSORIASIS; YOUNG ADULT;

EID: 84897560318     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004179     Document Type: Article

References (28)

1. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7. (Pubitemid 36871763)
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41(3 Pt 1):401-7. (Pubitemid 29418506)
3. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84. (Pubitemid 47071926)
4. Smith CH, Barker JN. Psoriasis and its management. BMJ 2006;333:380-4. (Pubitemid 44298066)
5. NICE. Psoriasis: the assessment and management of psoriasis. National Institute for Health and Clinical Excellence - Clinical Guidelines, 2012.
6. SIGN. Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. A national clinical guideline. Vol. 121. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN), 2010:65.
7. Nast A, Boehncke WH, Mrowietz U, et al. S3 - guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012;10(Suppl 2):S1-95.
8. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019.
9. SBD. Consenso Brasileiro de Psoríase 2012 - Guias de avaliação e tratamento Sociedade Brasileira de Dermatologia. 2nd edn. Rio de Janeiro: Sociedade Brasileira de Dermatologia, 2012.
10. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64:1035-50.
11. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
12. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794.
13. Psoriasis: the assessment and management of psoriasis. National Institute for Health and Clinical Excellence - Clinical Guidelines, 2012.
14. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. American Academy of Dermatology, 2008.
15. Papp K, Gulliver W, Lynde C, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011;15:210-19.
16. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70.
17. GRUPO. IBOPE INTELIGÊNCIA. Coleta de dados. Diversos métodos para atender à sua demanda. Publicação em 28/04/2009. http://www.ibope.com.br (Acesso em 28 ju. 2011) 2011.
18. LIPE. PESQUISAS. Dúvidas frequentes: o que é CATI? Disponível em http://www.lipe.com.br . (Acesso em 28 jul. 2011) 2011.
19. Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother 2006;7:157-67. (Pubitemid 43263255)
20. Pearce DJ, Thomas CG, Fleischer AB Jr, et al The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs 2004;16:421-8, 432.
21. Lucka TC, Pathirana D, Sammain A, et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012;26:1331-44.
22. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:513-26.
23. Naldi L, Rznay B. Psoriasis (chronic plaque). Clin Evid 2009;1706:1-109.
24. Vieira FS, Zucchi P. Distorções causadas pelas ações judiciais à política de medicamentos no Brasil. Rev Saúde Pública 2007;41:214-22.
25. Biehl J, Amon JJ, Socal MP, et al. Between the court and the clinic: lawsuits for medicines and the right to health in Brazil. Health Hum Rights 2012;14:E36-52.
26. Chieffi AL, Barata RB. ['Judicialization' of public health policy for distribution of medicines]. Cad Saude Publica 2009;25:1839-49.
27. Grimshaw JM, Eccles MP, Lavis JN, et al. Knowledge translation of research findings. Implement Sci 2012;7:50.
28. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65. (Pubitemid 29493800)